Vanguard Asset Management
CGEM icon

Vanguard Asset Management’s Cullinan Oncology CGEM Stock Holding History

Vanguard Asset Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$585K Buy
32,137
+12,092
+60% +$180K ﹤0.01% 2127
2026
Q1 		$285K Buy
+20,045
New +$258K ﹤0.01% 2302

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Vanguard Asset Management's CGEM Position: Q2 2026 in Review

Vanguard Asset Management increased its Cullinan Oncology (CGEM) stake by 60% in Q2 2026, buying an estimated $180K and bringing the position to 32,137 shares worth $585K. The position accounts for ﹤0.01% of the portfolio, ranked #2127.

Vanguard Asset Management first reported a position in CGEM in Q1 2026 and has held it in 2 quarters since. 167 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Vanguard Asset Management held 32,137 shares of Cullinan Oncology worth $585K as of Q2 2026.
  • Vanguard Asset Management bought 12,092 Cullinan Oncology shares in Q2 2026, an estimated $180K.
  • Cullinan Oncology made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2127 holding.
  • Vanguard Asset Management first reported a position in Cullinan Oncology in Q1 2026 and has held it in 2 quarters since.
  • 167 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.